Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
A requirement for entering the trial was to have established cardiovascular disease and thus be at high risk of an event, such as stroke, heart attack, or cardiovascular-related death
Bortezomib and carfilzomib, FDA-approved for cancer, reduce autoantibody levels and suppress IFN- production by plasmacytoid dendritic cells, slowing SLE progression
Inhaled glutathione is another method of administration, sometimes used in clinical settings, but it can cause respiratory side effects, especially in people with asthma
Pharmacokinetics: Scopolamine is rapidly and fully distributed into the CNS where it has greater effects than most other antimuscarinics
18 December 2024
This information is for educational purposes and is not a substitute for professional medical consultation.
US$ 24.91
US$ 25.85
US$ 28.04
